PEPGEN INC. Unrecognized Tax Benefits, Income Tax Penalties Expense
PEPGEN INC. (PEPG) reported Unrecognized Tax Benefits, Income Tax Penalties Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties › Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense · last filed 2026-03-04
- PEPGEN INC. unrecognized tax benefits, income tax penalties expense for the quarter ending 2024-06-30 was $0.00.
- PEPGEN INC. unrecognized tax benefits, income tax penalties expense for the quarter ending 2024-03-31 was $0.00.
- PEPGEN INC. unrecognized tax benefits, income tax penalties expense for the quarter ending 2023-12-31 was $0.00.
- PEPGEN INC. unrecognized tax benefits, income tax penalties expense for the quarter ending 2023-09-30 was $0.00.
- PEPGEN INC. unrecognized tax benefits, income tax penalties expense for fiscal 2025 was $0.00.
- PEPGEN INC. unrecognized tax benefits, income tax penalties expense for fiscal 2024 was $0.00.
- PEPGEN INC. unrecognized tax benefits, income tax penalties expense for fiscal 2023 was $0.00.
- PEPGEN INC. unrecognized tax benefits, income tax penalties expense for fiscal 2022 was $0.00.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties Expense 3 month | Unrecognized Tax Benefits, Income Tax Penalties Expense 6 month | Unrecognized Tax Benefits, Income Tax Penalties Expense 9 month | Unrecognized Tax Benefits, Income Tax Penalties Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-04 | |||
| 2024-12-31 | $0.00 10-K · filed 2025-02-24 | |||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $0.00 derived: sum of 3 quarters · filed 2024-08-08 | $0.00 derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-14 | $0.00 derived: sum of 2 quarters · filed 2024-05-14 | $0.00 derived: sum of 3 quarters · filed 2024-05-14 | $0.00 derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $0.00 derived: sum of 3 quarters · filed 2024-03-29 | $0.00 10-K/A · filed 2024-03-29 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | $0.00 derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $0.00 derived: sum of 3 quarters · filed 2023-08-08 | $0.00 derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2023-05-11 | $0.00 derived: sum of 3 quarters · filed 2023-05-11 | $0.00 derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $0.00 derived: sum of 3 quarters · filed 2023-03-23 | $0.00 10-K · filed 2023-03-23 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $0.00 10-Q · filed 2022-08-12 | ||
| 2022-03-31 | $0.00 10-Q · filed 2022-06-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |